A newly expanded view of how asthma inflammation starts
Researchers at National Jewish Health have identified a previously unrecognized mechanism that appears to help drive allergic asthma, centering on a protein called CBX7. The work, published in Science Advances, suggests that CBX7 does more than its established role in regulating gene activity inside the nucleus. In the new study, the protein also acted in ways that helped switch on and sustain inflammatory signaling in immune cells after allergen exposure.
That finding matters because allergic asthma is not just a matter of irritated airways. It is a chronic inflammatory disease in which immune cells release signaling molecules that amplify swelling, mucus production, and airway sensitivity. Current treatments can reduce symptoms and suppress inflammation, but the new results point to a more upstream control point: a molecular component that may help initiate and maintain the inflammatory response itself.
What the team found
The study focused on how immune cells behave when exposed to allergens. According to the researchers, CBX7 became activated after that exposure and then promoted inflammation through what they described as a dual mechanism. In one role, the protein functioned in the cytoplasm as a chemical messenger. In another, it relayed information to the nucleus, where it worked with other transcription factors to promote cytokine production.
Cytokines are among the immune system signals most closely tied to asthma-related inflammation. When their production rises and remains elevated, the result can be a self-reinforcing cycle of immune activation. The team reported that CBX7 helped support exactly that kind of sustained signaling, keeping relevant immune cells active and prolonging inflammatory responses associated with allergic asthma.
Researchers also found that reducing CBX7 activity in immune cells significantly lowered the production of inflammatory cytokines. That result strengthens the case that CBX7 is not merely associated with the response, but is playing an active functional role in it.
Why CBX7 stands out
One of the notable aspects of the study is that CBX7 was previously believed to primarily suppress gene activity in the cell nucleus. The new work instead describes a broader role, including the ability to activate inflammatory genes and support signaling pathways outside the nucleus as well. That changes how the protein may be understood in the context of immune biology.
Senior author Rafeul Alam said the findings show that CBX7 has a much larger role in immune cell function than previously appreciated. In practical terms, that means researchers may now have a more precise molecular handle on one piece of the inflammatory machinery that underlies allergic asthma.
The distinction is important. Many asthma therapies are designed to control inflammation after it is underway or to manage symptoms such as airway constriction. A target involved earlier in the chain could eventually support treatments aimed at interrupting the process before it fully escalates.
Implications for future therapies
The study does not present a new treatment, and it does not suggest that patients are close to seeing CBX7-targeted drugs in the clinic. But it does identify what the researchers describe as a critical control point in the inflammatory behavior of certain immune cells involved in asthma.
If that role holds up in further studies, CBX7 could become a candidate for therapies designed to more selectively modulate immune activity. That would be especially relevant in asthma, where one of the ongoing challenges is balancing disease control with treatment specificity. A more precise intervention could, in principle, reduce harmful inflammation without broadly suppressing immune function.
The appeal of that strategy is clear. Allergic asthma affects patients with widely varying severity, triggers, and responses to existing medicines. Some do well with inhaled therapies and biologic drugs, while others continue to experience persistent inflammation and flare-ups. A newly identified molecular switch could broaden the future treatment toolkit, particularly if it helps explain why some inflammatory pathways remain active despite current approaches.
What the research does and does not show
At this stage, the findings are best understood as mechanistic. They clarify how a protein behaves in immune cells and how that behavior may contribute to disease. They do not establish a finished drug strategy, and they do not demonstrate clinical benefit in patients from blocking CBX7.
That said, mechanistic discoveries often define the next phase of translational work. Once a target is identified and its function becomes clearer, researchers can begin testing whether inhibiting or modulating it can safely reduce disease activity in more realistic biological settings. In asthma, where inflammation is shaped by complex interactions between allergens, airway tissues, and multiple immune cell types, those next steps will matter.
The study also highlights how much remains to be learned about proteins that may have more than one role inside cells. A molecule once classified mainly as a suppressor of gene activity can turn out to have signaling functions that make it highly relevant to inflammatory disease. That is the sort of shift that can open new research directions well beyond a single disorder.
Why this discovery could matter broadly
Although the immediate focus is allergic asthma, the broader lesson concerns immune regulation. Proteins that can operate across cellular compartments and influence both messaging and gene activation are often positioned to shape larger networks of inflammation. If CBX7 proves to be such a node, interest in it may extend beyond asthma into other immune-mediated conditions.
For now, the most important outcome is that researchers have identified a plausible new driver of asthma-related inflammation and shown that reducing its activity can dampen cytokine production in immune cells. That gives the field a clearer biological pathway to investigate and a potential new target to test.
In a disease area where many treatments focus on controlling consequences, the possibility of disrupting one of the initiating and sustaining signals is significant. The work does not rewrite asthma care overnight, but it does sharpen the map of where future therapies may aim.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
